Most prostate cancers express androgen receptor (AR), and our previous studies have focused 26 on identifying transcription factors that interact with and modify AR function. We have shown that 27 transcription factor nuclear factor I/B (NFIB) regulates androgen receptor (AR) activity and that its 28 expression is decreased in the luminal cells of severe benign prostatic hyperplasia. To assess 29 whether changes in NFIB expression are associated with prostate cancer progression, we 30 immunostained a tissue microarray including normal, hyperplastic, prostatic intraepithelial 31 neoplasia, primary prostatic adenocarcinoma, and castration-resistant prostate cancer tissue 32 samples for NFIB, AR, and synaptophysin, a marker of neuroendocrine differentiation. We 33 observed increased NFIB in the nucleus and cytoplasm of prostate cancer samples independent 34 of Gleason score. We also observed strong NFIB staining in primary small cell prostate cancer. 35
minutes), 100% ethanol (2 x 2 minutes), 95% ethanol (2 x 2 minutes), 70% ethanol (1 x 2 minutes), 141 50% ethanol (1 x 2 minutes). Slides were then washed in running tap water for 3 minutes and 142 placed in a container with citric acid-based antigen unmasking solution (H-3300, Vector). Slides 143 were then placed in a pressure cooker and cooked on high pressure for 25 minutes. Following 144 pressure release, slides were allowed to cool for 25 minutes prior to subsequent steps. Slides 145 were washed in 1 X PBS (3 x 10 minutes). Endogenous peroxidase activity was blocked with a 146 20-minute incubation of slides in peroxidase blocking solution (2.5ml of 30% hydrogen peroxide 147 into 250ml methanol). Slides were again washed in 1X PBS (3 x 10 minutes). The tissue 148 microarray was outlined with a PAP pen, and blocking solution (50μl of horse serum in 3 ml PBS) 149 was added to slides for 30-minutes at room temperature. Blocking solution was removed and 150 primary antibodies (1:1000) were added to each slide and incubated at 4°C overnight. In the 151 morning, slides were washed in 1X PBS (3 x 10 minutes) before secondary antibody (1: 200, 152 Vector) was added for an hour at room temperature. While slides were washed in 1X PBS (3 x 10 153 minutes), A and B components (2 drops A, 2 drops B into 5 ml PBS, VECTASTAIN Elite ABC 154 HRP Kit) were combined to incubate for 30 minutes. AB solution was then added to slides and 155 incubated at room temperature for 60 minutes, followed by washes in 1 X PBS (3 x 10 minutes). 156
Slides were then developed with Liquid DAB+ Substrate Chromogen System (1 drop DAB+ per 157 ml of buffer, DAKO), quenched with water and counterstained as follows. Positive controls 158 (prostate for AR, NFIB, brain for synaptophysin) were used to set the exposure time, and all slides 159 in an antibody series were incubated for the same amount of time in DAB. Slides were washed 160 for 5 minutes in running tap water and then were placed in Harris hematoxylin (Richard Allan 161 Scientific) for 30 seconds, followed by 1 minute in running tap water and 10 dips in de-ionized 162 water. Slides were then dipped in Clarifier-2 for 3 times and rinsed 1 minute in running tap water 163 and 10 dips in de-ionized water. Rinsed slides were then placed in Bluing Reagent (Richard Allan 164 Scientific) for 10 dips and again rinsed 1 minute in running tap water and 10 dips in de-ionized 165 water. Slides were then dipped 10 times in 70% ethanol and dehydrated through 5 100% ethanol 166 baths, 10 dips each before finally being dehydrated in xylenes (3 x 4 minutes). Slides were cover-167 slipped with Cytoseal 60. 168 169 Cell lines: LNCaP (clone FGC, CRL-2876), JEG-3 (HTB-36), 22RV1 (CRL-2505), PC-3 (CRL-170 1435), and DU145 (HTB-81) cells were purchased from American Type Culture Collection 171 (ATCC). C4-2B 37 cells were provided by Drs. Ruoxiang Wu and Leland Chung (Cedars-Sinai) . 172
LNCaP, C4-2B, and 22RV1 were cultured in 10% premium fetal bovine serum (FBS, Atlanta 173 Biologicals S11150) in RPMI 1640 + L-glutamine (Gibco). JEG-3 and DU145 cells were cultured 174 in 10% FBS in MEM + Earle's salts and L-Glutamine (Gibco). PC-3 cells were cultured in 10% 175 FBS in F-12K Kaighn's modification + L-Glutamine (Gibco). , cells were provided by Dr. Simon Hayward (NorthShore Research Institute) 38, 39 . BHPrS-1 cells 177 were maintained in RPMI supplemented with 5% FBS and NHPrE-1 and BHPrE-1 cells in 178 F12/DMEM 1:1 medium containing 5% FBS, 1% Insulin-Transferrin-Selenium supplement, 10 ng/ml epidermal growth factor, 0.4% bovine pituitary extract and 1% antibiotic-antimycotic mix (all 180 from Gibco). 3D cultures of NHPrE-1 and BHPrE-1 cells were established in 8-well chamber slides 181 by plating 2,000 cells/well in medium containing 2% (vol/vol) Matrigel on top of an undiluted layer 182 of Matrigel. These cultures were grown for 9 days and cells were released from Matrigel using 183
Corning Cell Recovery Solution to prepare cell lysates for western blot analysis. 184 185 Plasmids: pCMV6-Entry (vector) and pCMV6-NFIB-myc-DDK (RC231240) were purchased from 186
Origene. The AR construct, p5HbHAR-A, used to generate AR-V7 and AR-V9 40 , was provided by 187
Dr. Scott Dehm (University of Minnesota). The PSA-EP-luciferase 26 construct was provided by 188
Dr. Robert Matusik (Vanderbilt University Medical Center) and the SV40-renilla construct was 189 purchased from Promega (pRL-SV40, E2231). Supernatants were collected by centrifugation at 13,750 rpm for 20 min at 4°C. Protein 195 concentration was quantified and equal amounts of protein were added to 2X SDS loading buffer 196 with 5% beta-mercaptoethanol. Nuclear and cytoplasmic extracts of LNCaP, C4-2B, 22RV1, 197 JEG-3, DU-145 and PC3 cells were prepared using NE-PER Nuclear and extraction reagents 198 (Thermoscientific, 78833). Equal amounts of cytoplasmic and nuclear protein extracts were 199 resolved on NuPAGE 4-12% Bis-Tris Gels and transferred to nitrocellulose membranes. 200
Membranes were blocked in 5% skimmed milk in TBS/0.1% Tween-20 (TBST) for 1 hour at room 201 temperature followed by incubation overnight at 4°C with indicated antibodies NFIB (HPA003956, 202 g for 10 min and used to infect LNCaP or C4-2B cells in 60-mm dishes with 0.5 mL of RPMI1640 249 medium containing 10% FBS. Two rounds of retrovirus infections were performed on 2 sequential 250 days in presence of 4.0 µg/mL of hexadimethrine bromide (Sigma). Cells were re-plated into 10 251 cm dishes 48 hours after the second infection and allowed to grow in presence of puromycin 252 containing RPMI 1640 with 10% FBS for 4 days before they were used for further experiments. 2 253 µg/mL and 4 µg/mL of puromycin was used to select stable LNCaP and C4-2B cells. Whole cell 254 extracts from stable cells were checked for 3X-FLAG NFIB expression by western blotting using 255 FLAG M2 antibody (F1804, mouse antibody, 1:3000, Sigma). 256 Cytokine array: LNCaP and C4-2B vector and NFIB over-expressing cell lines were grown in 258 complete media. Cells were collected, lysed, and whole cell extracts were prepared as above. 259
Whole cell extracts were then applied to the Proteome Profiler Human XL Cytokine Array Kit per 260 manufacturer's instructions (R&D Systems). The Proteome Profiler Human XL Cytokine Array 261 includes 105 cytokines blotted in duplicate. Images were acquired as above, with each cell line 262 (vector and NFIB) imaged at the same time. Dotblot analysis was performed using ImageJ 43-45 . 263 First, the background was subtracted (rolling ball radius of 25 pixels) and the imaged inverted. A 264 circle was drawn around the positive control and integrated density was measured of each visible 265 dot plus two negative control areas. The difference between the integrated density of each dot 266 and the negative control was considered the true integrated density. For analysis by cell line, we 267 adjusted for membrane variability by generating a ratio of vector-to-NFIB positive controls. We 268 lysed, and luciferase and renilla expression was quantified using the Dual-Reporter assay system 280 (Promega) using a SpectraMax ID3 plate reader with a dual injection system. Luciferase data was 281 then normalized to renilla and then vector cells. 282 Statistical analysis: Statistical analysis was performed using SPSS 24 (IBM) or GraphPad Prism 284 and utilized non-parametric tests, with P values smaller than 0.05 considered significant. Dot plots 285 are overlaid with mean with standard deviation. 286 287
Results: 288
Our previous study of a small cohort of patients demonstrated that NFIB was frequently 289 lost in the luminal cells of patients with severe benign prostatic hyperplasia 34 . To determine 290 whether this was also true in prostate cancer patients, we stained a tissue microarray and several 291 core biopsies with an antibody against NFIB (Figure 1 , Supplemental Figure 1A , B), which we had 292 previously validated in Nfib knockout mouse tissues 34 . In order to determine whether changes in 293 NFIB expression were associated with changes in AR or acquisition of neuroendocrine features, 294
we also stained the tissue microarray for synaptophysin. Staining was then scored by a board-295 certified genitourinary pathologist (GG). 296
Using an average patient score, we compared the expression of NFIB, AR, and 297 synaptophysin in normal prostate and prostate cancer (Figure 2 A-C). NFIB was over-expressed 298 in the nucleus (P = 0.0259) and cytoplasm (P < 0.0001) of cancer tissues versus patient matched 299 normal prostate tissues. While AR was not over-expressed in the nucleus, cytoplasmic AR was 300 increased in prostate cancer tissues versus normal prostate (P < 0.0001). Synaptophysin staining 301 was limited to the cytoplasm and cell membrane, and also increased in prostate cancer tissues 302 (P < 0.0001). 303
To evaluate whether NFIB, AR, and synaptophysin expression corresponded with 304
Gleason grade, we generated average scores per each unique core. There was no statistically 305 significant difference between Gleason grade 3 versus 4 or Gleason grade 3 versus 5 for AR, 306 NFIB, or synaptophysin (Figure 2 D-F). Using these values, we also correlated the expression of 307 nuclear and cytoplasmic NFIB with AR and synaptophysin. In primary prostate cancer samples, 308 nuclear and cytoplasmic NFIB levels were positively correlated (Spearman rho = 0.305, P = 309 0.001), suggesting that NFIB expression increases in both compartments and that increasing 310 cytoplasmic expression is not due to a shift in cytolocalization (Supplemental Figure 2A ). Nuclear 311 NFIB was also positively correlated with nuclear AR (Spearman rho = 0.419, P < 0.0001). 312
Cytoplasmic NFIB was positively correlated with nuclear AR (Spearman rho = 0.248, P = 0.006), 313 cytoplasmic AR (Spearman rho = 0.447, P < 0.0001), and synaptophysin (Spearman rho = 0.464, 314 P < 0.0001). The positive correlation of cytoplasmic NFIB with synaptophysin remained intact 315 whether we examined all prostate cancer tissues (primary and castration-resistant) or castration-316 resistant only (Supplemental Figure 2B , C). 317
We also examined whether NFIB expression correlated with biochemical recurrence in 51 318 primary prostate cancer patients for who we had biochemical recurrence data. For these patients, 319
we again used the average NFIB nuclear and cytoplasmic score ( Figure 3A ). Nuclear and 320 cytoplasmic NFIB staining did not correlate with biochemical recurrence (Figure 3B , C). However, 321 when we examined a ratio of cytoplasmic and nuclear NFIB, we found a high ratio of cytoplasmic-322 to-nuclear NFIB predicted earlier biochemical recurrence (P = 0.058; hazard ratio 2.864; 95% CI 323 0.966 -8.491; Figure 3D , E), an effect that achieved statistical significance when surgical 324 resection margin status was accounted for in the Cox regression model (P = 0.004; hazard ratio 325 8.930; 95% CI 1.989 -40.086; Figure 3F ). There was no difference in cytoplasmic-to-nuclear 326 NFIB by Gleason grade or tumor stage (Supplemental Figure 3A ) 327
To more fully explore NFIB expression in the normal and diseased prostate, we compared 328 NFIB average patient scores in unmatched patient samples, using unpaired analysis ( Figure 4A Figure 3A) . 331
While there was no statistically significant difference between nuclear NFIB staining in primary 332 prostate cancer versus normal tissue or castration-resistant prostate cancer, cytoplasmic NFIB 333 was again increased in primary prostate cancer versus normal prostate tissue (P < 0.0001) but 334 not castration-resistant samples. While nuclear AR expression was unchanged, cytoplasmic AR was decreased in normal prostate samples (P = 0.0002) and increased in castration-resistant 336 samples (P = 0.0038), versus primary prostate cancer ( Figure 4B ). Synaptophysin expression 337 was also significantly lower in normal prostate tissue versus prostate cancer (P = 0.007), but there 338 was no significant difference between primary prostate cancer and castration-resistant ( Figure  339 4C). 340
Because only one of our castration-resistant prostate cancer cases satisfied our criteria 341 for neuroendocrine features (loss of AR, strong synaptophysin staining), we also analyzed a 342 limited number (n=8) of primary small cell prostate cancer core biopsies. Of these, 7 (88%) 343 showed strong nuclear NFIB staining (Supplemental Figure 1B) . Small cell prostate cancer cells 344 have limited cytoplasm, so NFIB expression was not scored. 345
In order to evaluate whether established prostate cancer cell lines recapitulate the nuclear 346 and cytoplasmic expression of NFIB, we performed nuclear and cytoplasmic protein isolation from 347 prostate cancer cell lines. We examined androgen-dependent (LNCaP), castration-resistant (C4-348 2B, 22RV1), and AR-independent (DU-145, PC3) prostate cancer cells. As a control, we used 349
JEG-3 cells which express limited NFIB based on previous reports and gene expression 350
analysis 29, 46 . NFIB isoforms were found in all cell lines ( Figure 5A ), including benign stromal and 351 epithelial cells (Supplemental Figure 4A ). NFIB exists as four isoforms in most prostate cancer 352 cell lines, at 62 kDa, 57 kDa, 49 kDa, and 39 kDa (Supplemental Figure 4B) . 353
In order to verify which of these bands are true NFIB bands, we performed transient 354 transfections and over-expression studies. First, we transiently transfected PC-3 cells with NFIB 355 over-expression or NFIB-knockdown constructs and compared which bands were impacted 356 (Supplemental Figure 4C ). In PC-3 cells, transient NFIB over-expression gave rise to a 53kDa 357 band. Importantly, all other putative NFIB isoforms increased as well (62 kDa, 57 kDa, 49 kDa 358 and 39 kDa), suggesting that NFIB auto-regulates its own expression. Transient transfection of 359 an NFIB-targeting siRNA also decreased expression of the 62kDa, 57 kDa, and 49 kDa bands, 360
suggesting that these bands do indeed represent NFIB. We also expanded this analysis to JEG-3, LNCaP, C4-2B, and 22RV1 cells. In the LNCaP and C4-2B cells, transient knockdown abrogated 362 expression of both the 57 kDa and 49 kDa bands (Supplemental Figure 4D ). Neither of these 363 were expressed in JEG-3 cells. In 22RV1 cells, NFIB knockdown also decreased expression of 364 the 62 kDa band, which was not impacted in JEG-3, LNCaP, or C4-2B cells. However, as this 365 band increased in response to NFIB over-expression and decreased in both 22RV1 and PC-3 366 cells in response to transient knockdown, we consider it an NFIB isoform. Finally, although the 367 39 kDa band was not decreased in response to transient knockdown in the prostate cancer cells, 368 its expression was limited in JEG-3 cells, and its expression increased in the NFIB-overexpressing 369 cell lines. 370
Because cytoplasmic NFIB expression in prostate cancer patient tissues was higher in 371 castration-resistant samples, we compared NFIB localization in LNCaP, C4-2B, and 22RV1 cells 372 ( Figure 5B ). In LNCaP cells, which are androgen-dependent, NFIB is largely in the nucleus, but 373 as cells progress to castration resistance in C4-2B cells, NFIB expression increases in both the 374 nuclear and cytoplasmic fractions. These levels are even more pronounced in the unrelated Since AR and NFIB are frequently co-occupying the same cellular compartment, AR and 378 NFIB co-occupy the same genomic regions in a prostate cancer cell line, and our previous studies 379 determined NFIB regulates AR-target gene expression 29,34 , we evaluated whether NFIB and AR 380 can interact directly by transfecting NFIB and AR into JEG-3 cells, which express low levels of 381 NFIB. Indeed, in transient transfection co-immunoprecipitation experiments, NFIB and AR co-382 immunopurify ( Figure 5C ). 383
To start elucidating the roles of NFIB in primary and castration-resistant prostate cancer, 384
we turned to well-defined in vitro models. We focused on two related cell lines: LNCaP cells are 385 androgen-dependent, while their bone-homing metastatic derivative C4-2B cells are castration-386 resistant. We generated pBABE (vector) or 3X-FLAG-NFIB over-expressing LNCaP and C4-2B cells ( Figure 5D ). Cell lines were positive for the Flag-tagged NFIB (53 kDa) and also showed 388 increased endogenous NFIB expression (53 kDa, 49 kDa, 39 kDa). This observation was 389 consistent with our previous experiments, where transient over-expression of NFIB induced 390 increased expression of multiple NFIB isoforms in PC-3 cells (Supplemental Figure 3C) . 391 Importantly, only one band was detected by the Flag antibody, indicating NFIB is not degraded, 392 but rather exists as a series of isoforms. We did not observe any changes in AR protein expression 393 in these cells ( Figure 5D ). 394
To examine some of the downstream targets of NFIB over-expression, we compared 395 cytokine expression using proteome profiling. The arrays included 102 cytokines and secreted 396 proteins, including prostate specific antigen (PSA) and IL-6, which has been implicated in 397 neuroendocrine differentiation 47-50 . In LNCaP cells, NFIB over-expression dramatically induced 398 PSA, along with DPPIV, GDF-15, and IGFBP-2; angiogenin, EGF, cystatin C, resistin, 399 pentraxin-3, and CD71 were also induced, but to a smaller extent ( Figure 6A, B) . In C4-2B cells, 400 over-expression of NFIB induced small changes in angiogenin and EGF. Importantly, over-401 expression of NFIB in LNCaP cells resulted in expression of PSA, GDF-15, and IGFBP-2 402 comparable to their castration-resistant derivative ( Figure 6C) . 403
To confirm that PSA expression is indeed regulated by NFIB, we performed reporter 404 assays in our two cell lines using a prostate specific antigen enhancer and promoter (PSA-EP 26 ) 405 element linked to luciferase. In both LNCaP and C4-2B cells, over-expression of NFIB resulted in 406 increased PSA-EP reporter activity ( Figure 6D , E), increasing AR activity by 1.2 fold and 1.4 fold 407 versus parental cell lines respectively (P < 0.01). 408 409
Discussion: 410
The goal of our study was to define the expression of NFIB in prostate cancer with respect 411 to AR and synaptophysin and to begin to unravel the relationship between NFIB and prostate 412 cancer progression. We analyzed a tissue microarray composed of cores including normal, BPH, prostate cancer, and castration-resistant prostate cancer tissues samples. On a matched per-414 patient basis, NFIB is over-expressed in both the nuclear and cytoplasmic compartments in 415 primary prostate cancer versus normal prostate tissue. Importantly, increasing nuclear NFIB 416 expression corresponds with increasing cytoplasmic expression, suggesting that NFIB continues 417 to occupy the nucleus in prostate cancer. Indeed, there is no statistically significant difference 418 between primary and castration-resistant prostate cancer in terms of nuclear or cytoplasmic NFIB 419 expression. 420
There also was not a significant difference between NFIB expression in either 421 compartment when compared by Gleason pattern, enabling us to evaluate the utility of NFIB as 422 predictor of biochemical recurrence, independent of Gleason grade. While nuclear NFIB or 423 cytoplasmic NFIB expression alone could not predict biochemical recurrence, a higher ratio of 424 cytoplasmic-to-nuclear NFIB predicted earlier time to biochemical recurrence when we accounted 425 for surgical margin status in the Cox regression analysis. This observation is exciting, but a 426 limitation to our analysis is the sample size as well as the challenge of generating both a 427 cytoplasmic and nuclear score for each patient. While these limitations limit the utility of NFIB as 428 biomarker of biochemical recurrence, these observations do suggest NFIB plays an interesting in 429 prostate cancer biology. 430
Consistent with our human tissue data, NFIB is expressed in the nuclear and cytoplasmic 431 fractions of prostate cancer cells. As in castration-resistant prostate cancer, castration-resistant 432 prostate cancer cell lines have increased levels of NFIB in both the nuclear and cytoplasmic 433 compartments compared to androgen-dependent prostate cancer cells. Consistent with UniProt 434 predicted isoforms, we report that NFIB also exists in multiple isoforms in prostate cancer cells, 435 with average molecular weights of 62 kDa, 57 kDa, 49 kDa, and 39 kDa. 436
Our observation of multiple NFIB isoforms is novel in prostate cancer cell lines, but has 437 been reported in other systems. The NFIB gene can undergo alternative splicing, giving rise to 438 nine variants 51 , and the presence of multiple NFIB protein isoforms is consistent with reports from 439 UniProt 52 , where NFIB has six reported isoforms (O00712 [NFIB_HUMAN], Entry version 172 [08 440
May 2019]). These isoforms have molecular weights of 47,442 Da (O00712-1), 22,251 Da 441 (O00712-2), 53,049 Da (O00712-4), 55,181 Da (O00712-5), and 33,525 Da (O00712-6). While 442 these do not match up exactly with our reported bands at 62 kDa, 57 kDa, 49 kDa, and 39 kDa, 443 NFIB a can undergo posttranslational modification like glycosylation 53 and sumoylation 54 which 444 could add to these molecular weights. In vitro translation assays have also identified NFI-B2 and 445 NFI-B3, at 47 kDa and 22 kDa, respectively 55 , indicating that some of these splice variants are 446 expressed and functional. Significantly, the NFI-B3 isoform lacks the ability to bind DNA and 447 regulate gene expression and acts as a dominant negative factor in the presence of NFIB, NFIC, 448 and NFIX 55 Unfortunately, the NFIB antibody immunogen is a sequence shared by all but the 449 22,251 Da (O00712-2) isoform. Therefore, we do not know the status of this isoform in our 450 prostate cancer cell lines or prostate cancer tissues. 451
Although our previous studies showed that FOXA1 bridges the AR/NFIX interaction in 452
HeLa cells in Fluorescent Protein Förster Resonance Energy Transfer (FP-FRET) experiments 29 , 453
we did observe some FRET signal between AR and NFIX, albeit this signal did not achieve 454 statistical significance. Our exogenous co-immunoprecipitation studies now demonstrate at least 455 one NFI, NFIB, is capable of interacting with the full length AR. What domains are responsible for 456 this interaction, whether this interaction occurs with AR splice variants, and what the functional 457 consequences of AR and NFIB interaction entail is under investigation. 458
In this present study, we investigated the role of NFIB in disease progression by using 459
LNCaP and their castration-resistant derivative cell line, C4-2B as a model of disease 460 progression. Over-expression of NFIB induced expression of PSA in LNCaP cells to levels 461 comparable with C4-2B cells. Our data supports that this is likely due to interactions with AR, as 462
we observed no increase in AR protein expression but instead noted increased AR activity in an secreted proteins and cytokines associated with and/or implicated in castration-resistant prostate 465 cancer, such as angiogenin 56 , DDPIV (CD26) 57 , IGFBP-2 58, 59 , and PSA 60 . 466 These studies linking NFIB with more aggressive disease are more consistent with the 467 literature, wherein NFIB has been recently considered a proto-oncogene 61-66 . Our early studies 468 indicated that transient knockdown of NFIB increased the expression of AR-target genes 29, 34 , and 469 we believe this difference might be due to the adaptation that NFIB over-expression induces. For 470 example, in mouse models of lung cancer, Nfib increases chromatin accessibility 64 , potentially 471 through interactions with FOXA1 we have demonstrated previously 29 . NFIB has also been 472 implicated in controlling components of the Polycomb Repressive Complex 2 (PRC2), which 473 includes EZH2 and EED. Over-expression of NFIB induces expression of EZH2 in melanoma 62 474 and NFIB also interacts with EED 67 . 475
Although our studies have focused on the role of NFIB in regulating AR expression and 476 activity, it is likely that NFIB also has roles independent of AR. For example, in mouse models of 477 small cell prostate cancer or lung cancer, Nfib is regularly amplified 68,69 , and over-expression of 478
Nfib in a transgenic model of small cell lung cancer drives aggressive disease 63 . Our small cohort 479 of primary small cell prostate cancer samples strongly express NFIB. What the role for NFIB in 480 these AR-independent tumors also remains to be determined. 481
In summary, our study has described the expression of NFIB, AR, and synaptophysin in 482 a small cohort of prostate cancer patients. We report that NFIB is over-expressed in the nuclear 483 and cytoplasmic fractions of prostate cancer patient tissues and cell lines. We also report that 484 NFIB can interact with full length AR, and over-expression of NFIB can support increased 485 expression of canonical AR-target gene products, like PSA. 486 487
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